I

Inspire Medical Systems

FDA-approved neurostimulation device for OSA

Therapy Development Representative

Full-TimePosted on 10/16/2026
$105k+ Equity awards + Employee Stock Purchase Program
Mid
Bachelor's
Albuquerque, NM, USA
RemoteTravel within the territory/region, including overnight trips, may be required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree and at least 2 years of pharmaceutical, healthcare, or medical device sales experience are required.
  • In lieu of a bachelor's degree, at least 4 years of sales experience in the pharmaceutical, healthcare, or medical device industry, or 2 years of experience working directly with Inspire Medical Systems therapy in a clinical setting, is required.
  • Ability to travel within the territory or region, including overnight travel, as needed.
  • Referral development or market development experience is preferred.
  • Territory support or account management experience is preferred.
  • Clinical experience supporting healthcare providers is preferred.
  • Communication, negotiation, and relationship-building skills are preferred.
  • Presentation skills are preferred.
  • Business acumen is preferred.
  • Proficiency in Microsoft Office Suite and customer relationship management tools is preferred.
  • Willingness to relocate for advancement opportunities is preferred.
  • A valid driver's license, proof of insurance, and/or reliable transportation are required to travel to hospitals, clinics, and customer sites.
  • Ability to lift and move materials or equipment weighing up to 40 pounds and routinely stand, sit, bend, and reach, with or without reasonable accommodation, is required.
Responsibilities
  • Drive therapy development awareness by educating providers in the community, with the goal of growing the pipeline and converting patients to therapy.
  • Plan and execute a weekly customer-targeting sequence.
  • Educate primary care physicians, internal medicine providers, cardiologists, and other providers who treat or manage patients with obstructive sleep apnea to develop customer confidence.
  • Execute referral-channel growth initiatives to increase patient identification and therapy adoption.
  • Support monthly community education programs and awareness events.
  • Partner with Territory Managers to deepen physician engagement and identify practice growth opportunities, including local peer-to-peer events.
  • Conduct market assessments to identify growth opportunities and referral gaps.
  • Support Territory Managers in growing the territory pipeline and increasing pipeline conversion.
  • Communicate weekly with the aligned Territory Manager.
  • Log customer engagements and create new physician profiles in the customer relationship management system.
  • Transition customers from unaware to advocacy belief.
  • Provide clinical coverage as needed, secondary to referral development responsibilities.
  • Develop an understanding of implant procedures, patient pathways, and therapy delivery processes.
  • Maintain compliance with quality system requirements and field reporting obligations.
  • Understand and explain clinical and outcomes data to the referral community.
  • At the discretion of the Area Vice President and Regional Manager, complete training requirements for therapy activation and implant procedures.
Desired Qualifications
  • The position may offer compensation through equity awards and the Employee Stock Purchase Program.

About the company

I

Inspire Medical Systems

View

Inspire Medical Systems develops and sells a minimally invasive implantable device for obstructive sleep apnea (OSA). Its lead product, the Inspire system, uses implanted neurostimulation to activate the hypoglossal nerve, which moves the tongue and other airway muscles to keep the airway open during sleep. Patients control the therapy with a small handheld remote. The system targets adults with moderate to severe OSA who cannot use or benefit consistently from CPAP. Unlike non-implant options, Inspire provides a hands-free, on-demand airway support during sleep and is the first FDA-approved neurostimulation treatment for OSA. The company differentiates itself by offering a clinically approved implantable alternative to CPAP, backed by a direct US sales force and a network in Europe. Its goal is to provide an effective, durable option for patients who struggle with CPAP, expanding access to neurostimulation therapy to improve sleep quality and health outcomes.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Golden Valley, Minnesota

Founded

2007

Get referred to Inspire Medical Systems

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 Project Horizon targets $30 million annualized investment capacity by 2027.
  • September 2026 conference materials said coding clarity improved and WISeR-state billing issues eased.
  • CMS proposed 2027 facility-rate increases of 12% to 15%, supporting procedure economics.

What critics are saying

  • The January 2026 class action alleges Inspire V launch failures and misleading disclosures.
  • Medicare coding disruption cut second-quarter revenue $40 million; management expects $120 million-$130 million full-year impact.
  • If reimbursement stalls again before 2028 CPT approval, Inspire's growth thesis breaks quickly.

What makes Inspire Medical Systems unique

  • Inspire remains the only FDA-approved hypoglossal nerve stimulator for moderate-to-severe OSA.
  • The 2026 launch of Inspire V strengthened procedure simplicity and 3.0T MRI compatibility.
  • Direct U.S. sales and distributor coverage give Inspire tight control over adoption and education.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Unlimited Paid Time Off
  • Tuition Reimbursement
  • Employee Assistance program
  • Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Aug 20th, 2026
BrightSpring Health Services posts 23.9% revenue growth as Solventum and Inspire Medical face headwinds

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.

Yahoo Finance
Aug 7th, 2026
Inspire Medical shares surge 28.1% after Q2 earnings beat and raised 2026 guidance

Inspire Medical Systems shares have risen 28.1% in the past month following a second-quarter earnings beat and raised 2026 guidance. The company reported adjusted earnings of 14 cents per share, surpassing consensus estimates for a 22-cent loss, whilst revenues of $200.6 million exceeded expectations despite declining 7.6% year over year. Management increased its 2026 revenue outlook to $835–875 million and raised adjusted earnings guidance to $1.05–$1.45 per share. The Zacks consensus estimate for 2026 earnings increased 34.7% over the past four weeks. However, coding challenges and prior authorisation programmes reduced second-quarter revenues by approximately $40 million. Management expects a full-year impact of $120–130 million and forecasts an 8–10% revenue decline in the third quarter.

Yahoo Finance
Aug 4th, 2026
Inspire Medical launches Project Horizon with $30M reinvestment to boost patient access amid reimbursement shifts

Inspire Medical Systems appointed AtriCure CEO Michael H. Carrel to its Board as director Casey M. Tansey plans to retire. The company reported quarterly revenue of $200.58 million and earnings of $0.14 per share, exceeding analyst expectations despite a year-on-year decline. Inspire raised its full-year outlook and launched Project Horizon, targeting $30 million in annualised investment capacity for patient access and education. The initiative comes alongside proposed reimbursement increases for its Inspire 5 procedure in 2027. The company's revenue narrative projects $987.4 million revenue and $67.1 million earnings by 2029. Investors are weighing the impact of Project Horizon against ongoing reimbursement and coding volatility affecting the firm's implant-based approach to obstructive sleep apnea treatment.

Yahoo Finance
Aug 3rd, 2026
Inspire Medical beats Q2 estimates with $200.6M revenue, raises full-year guidance to $855M

Inspire Medical Systems reported second-quarter revenue of $200.6 million, beating analyst estimates by 3% despite a 7.6% year-on-year decline. The medical technology company, which develops implantable devices for obstructive sleep apnea treatment, posted adjusted earnings per share of $0.14, significantly exceeding the consensus estimate of -$0.25. The company raised its full-year revenue guidance to $855 million at the midpoint, 1.4% above analyst expectations. Management also increased full-year adjusted EPS guidance to $1.25, a 25% rise. Adjusted EBITDA reached $38.9 million with a 19.4% margin, beating estimates by 40.5%. Following the results, Inspire Medical Systems' stock jumped 13.6%. CEO Tim Herbert attributed the performance to increased discipline whilst navigating evolving coding and reimbursement challenges.

Yahoo Finance
Aug 2nd, 2026
Inspire Medical Systems Q2 revenue expected to drop 10.3% year on year

Inspire Medical Systems will report Q2 earnings on Monday after the bell. The medical technology company is expected to see revenue decline 10.3% year on year, a reversal from the 10.8% increase recorded in the same quarter last year. Last quarter, Inspire Medical Systems reported revenues of $204.6 million, up 1.6% year on year, beating analysts' expectations. However, the company's full-year revenue and EPS guidance missed estimates significantly. Analysts have generally reconfirmed their estimates over the last 30 days. Inspire Medical Systems shares are up 3.6% over the past month, trading at $51.21 against an average analyst price target of $51.43. Peers Bausch + Lomb and Baxter recently beat Q2 revenue expectations, with shares rising 2.7% and 5.7% respectively following their results.